Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer

Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis,...

Full description

Bibliographic Details
Main Authors: Hong Zheng, Jia-Yu Liu, Feng-Ju Song, Ke-Xin Chen
Format: Article
Language:English
Published: China Anti-Cancer Association 2013-09-01
Series:Cancer Biology & Medicine
Subjects:
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/618
_version_ 1819207083551096832
author Hong Zheng
Jia-Yu Liu
Feng-Ju Song
Ke-Xin Chen
author_facet Hong Zheng
Jia-Yu Liu
Feng-Ju Song
Ke-Xin Chen
author_sort Hong Zheng
collection DOAJ
description Ovarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.
first_indexed 2024-12-23T05:17:51Z
format Article
id doaj.art-b5a3cd580fb34907905683afff5683e7
institution Directory Open Access Journal
issn 2095-3941
2095-3941
language English
last_indexed 2024-12-23T05:17:51Z
publishDate 2013-09-01
publisher China Anti-Cancer Association
record_format Article
series Cancer Biology & Medicine
spelling doaj.art-b5a3cd580fb34907905683afff5683e72022-12-21T17:58:46ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412013-09-0110312313010.7497/j.issn.2095-3941.2013.03.0012013030001Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancerHong Zheng0Jia-Yu Liu1Feng-Ju Song2Ke-Xin Chen3Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Epidemiology and Biostatistics, Tianjin Medical University Cancer Hospital and Institute, National Clinical Research Center of Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, ChinaOvarian cancer is one of the most lethal malignant gynecological tumors. More than 70% of patients with ovarian cancer are diagnosed at advanced stage. The 5-year survival in patients with advanced ovarian cancer is less than 30% because of the lack of effective biomarkers for diagnosis, prognosis, and personalized treatment. MicroRNA (miR) is a class of small noncoding RNAs that negatively regulate gene expression primarily through post-transcriptional repression. Many studies on tissue miR in ovarian cancer have been carried out and show great potential in clinical practice. However, tissue samples are not easily available because sampling causes injury. Researchers have started to focus on plasma/serum miR, assuming that blood samples may replace tissue samples in miR research in the future. Plasma/serum miR research is still in its early stages. Studies on its function in the early diagnosis of ovarian cancer have achieved some progress, but plasma/serum miR profiling for prognosis and personalized treatment of ovarian cancer remains unknown. A thorough understanding of the function of plasma/serum miR in ovarian cancer will facilitate early diagnosis and improve treatment for ovarian cancer.http://www.cancerbiomed.org/index.php/cocr/article/view/618Ovarian neoplasmsmicroRNAsbiological markersearly diagnosis
spellingShingle Hong Zheng
Jia-Yu Liu
Feng-Ju Song
Ke-Xin Chen
Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
Cancer Biology & Medicine
Ovarian neoplasms
microRNAs
biological markers
early diagnosis
title Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
title_full Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
title_fullStr Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
title_full_unstemmed Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
title_short Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer
title_sort advances in circulating micrornas as diagnostic and prognostic markers for ovarian cancer
topic Ovarian neoplasms
microRNAs
biological markers
early diagnosis
url http://www.cancerbiomed.org/index.php/cocr/article/view/618
work_keys_str_mv AT hongzheng advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer
AT jiayuliu advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer
AT fengjusong advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer
AT kexinchen advancesincirculatingmicrornasasdiagnosticandprognosticmarkersforovariancancer